Tagged with Novartis,

Global The top 20 pharmaceutical companies in the world for the past year, according to Pharmaceutical Executive’s latest annual rankings. Pfizer holds sway at the top of the leaderboard, with its BioNTech-partnered COVID-19 vaccine Comirnaty still generating an incredible USD 37.8 billion in 2022 and its COVID-19 antiviral Paxlovid adding a…

Belgium Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains behind many of its European counterparts. In a recent roadmap, the minister of health set out to improve the country’s…

Belgium Novartis is one of Belgian pharma’s biggest investors across manufacturing and R&D, contributing EUR 598.9 million to GDP in 2022, creating 4,403 direct and indirect jobs, and reaching 5,349,628 million patients via its locally available portfolio. 18 months into his role as Country President for BeLux, Federico Mambretti expands on…

Egypt As Egypt moves towards universal healthcare coverage for its 100 million-plus population, the country has become the fastest growing pharma market in the Middle East and Africa region with a value of USD 6.3 billion. Here are some of the key trends to watch in Egypt as identified by local…

Switzerland The latest news from Swiss pharma and healthcare, including the startling announcement that Switzerland is set to destroy a full nine million doses of expired Moderna COVID-19 vaccines, with over five million more likely to follow. Elsewhere, Swiss health insurance premiums are set to see their largest rise since 2010…

Egypt Sherif Amin, an 18-year industry veteran with 12 years of experience in oncology leadership roles across MEA, is the recipient of several awards, including the 2019 Oncology President Award, 2015 CEO Innovation Award, and 2014 MENA Leadership Award. A recent appointee as country president for Novartis Egypt, Amin describes how…

Global The FDA’s recent accelerated approval for Bluebird Bio’s gene therapy Skysona and its US list price of USD three million per treatment has reignited the global debate around drug pricing. Bluebird execs are keen to emphasise how life-changing such treatments are for a small number of patients; Skysona is indicated…

Singapore On World Heart Day 2022 Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of cardiovascular disease (CVD) as well as Novartis’ multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world’s population. Speaking at the outset…

Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…

Global After the prolonged underperformance of its generics division, Sandoz, Novartis has announced a spin off that will allow the company to focus on its core business and which is part of a broader paring down strategy. For Novartis, the separation of Sandoz would further support our strategy of building a…

China A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs, a new report by McKinsey that evaluates China’s impact on the global biopharma industry, AstraZeneca’s respiratory plans, and Gilead’s USD…

USA Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme Court’s overturn of the Roe v. Wade ruling on abortion the industry’s reaction has been far from consistent. While certain…